REPORTS
Lauren Deluca and Shasta Rayne Harner are global subject-matter experts on the use of public-private-partnerships. Over the years, they have co-written a number of publications on various topics surrounding their use in the United States, including analysis of the political and social impacts.
​
We encourage you to share the proceeding reports with your colleagues, associates, federal and state policymakers, as well as your friends and family, to maximize their impact and help advocate for tangible change.
Violation of A Nation
In 2016, the US Centers of Disease Control and Prevention issued federal guidelines on the use of opioid analgesics for the treatment of chronic pain.
CIAAG explores the historical steps to their issuance and reveals shocking findings of regulatory and policy changes that permit human clinical trials to take place without participant knowledge or informed consent.
​
Lauren Deluca and Shasta Harner, conducted 9 Congressional and Senatorial meetings in April 2019, presenting our findings within Violation of a Nation. As a result, we successfully advocated for the issuance of an FDA Safety Announcement against the practice of forced and/or abrupt discontinuation from opioid medications due to serve health risks.
A Crisis Exploited
This investigative research report explores the relationships between Physicians for Responsible Opioid Prescribing, Pacira Pharmaceuticals, American Chronic Pain Association, BioDelivery Sciences International, Indivior, Steve Rummler HOPE Foundation, FedUp! Rally, FedUp!
Coalition, Shatterproof and US Pain Foundation as well as their Board of Directors. We present the activities of these organizations and other federal agencies in the creation of the nation's opioid-sparing policies and overarching strategic plans. We explore subjects, such as, the 2016 CDC's Opioid Prescribing Guidelines, the National Pain Strategy, Inter-Agency Pain Research Coordinating Committee and Federal Pain Research Strategy.
Ethical Guidance in Public, Private-Partnerships
This report offers CIAAG's unique analysis and recommendations regarding the use of public-private partnerships.
An integral part of creating successful public, private-partnerships is ensuring proper systems are in place to address issues related to bias, conflicts of interest, and other acts of corruption; including, but not limited to: scientific fraud, anti-trust violations and/or data and financial market abuses.
2022 CDC Opioid Prescription Guidelines:
A CIAAG Analysis
In 2016, the Centers for Disease Control & Prevention published national guidelines on the prescription of opioid-based medications for the treatment of pain and illness. These guidelines recommended maximum daily values and other restrictions on the prescribing of opioid analgesics to treat pain.
​
CIAAG's provides an in-depth analysis the guideline update which uncovered serious conflicts of interest, author bias, and a lack of evidence to support the recommendations being made by the guideline itself. Throughout the revised guidelines, the author's repeatedly cite a lack of evidence or research and then proceed to advise these same modalities to be labeled "evidence-based best-practices" despite a total lack of supporting evidence.
​
These guidelines are now being used to direct patient care to engage in treatment modalities that little, to no evidence, of their efficacy. CIAAG's research reveals this was done in an effort to align patient care with desired research goals outlined by HHS Pain Management Task Force Report and the HEALTHY PEOPLE Campaign.